First Waterless Nasal Allergy Spray Approved for Children as Young as Four Years of Age JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVJF), (NYSE:TEVA) announced today that the U ...

On March 23, 2012, the U.S. Food and Drug Administration (FDA) approved QNASL ®. The product became available to patients by prescription in April 2012, making it the first marketed nonaqueous or "dry ...

Data to be Presented Regarding Impact on Sleep Quality and Nasal Symptom Relief at 24 Hours Post Dose in Patients with Seasonal and Perennial Allergic Rhinitis Data will be presented at the meeting ...

Teva announced that the Food and Drug Administration (FDA) has approved QNASL (beclomethasone dipropionate) 40mcg for the treatment of nasal symptoms associated with allergic rhinitis in children 4–11 ...

JERUSALEM, Israel, November 6, 2012 – Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL® (beclomethasone dipropionate) Nasal ...

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that data from four late-stage studies examining QNASL™ (beclomethasone dipropionate [BDP]) HFA, a nasal ...

JERUSALEM — Teva Pharmaeceuticals on Tuesday announced that the Food and Drug Administration accepted the company's supplemental new drug application for a lower dose QNASL (beclomethasone ...

NEW YORK (AP) -- Teva Pharmaceutical Industries Ltd. said Monday that the Food and Drug Administration approved Qnasl, a drug intended to treat nasal allergy symptoms. Qnasl is a once-per-day "dry" ...

Teva just got the OK for a new entry in the $2.5 billion market for nasal allergies aerosols. The Food and Drug Administration approved Teva’s QNASL, which the company (NASDAQ:TEVA) said is a “dry,” ...